Background-End stage (ES) is a recognized part of the hypertrophic cardiomyopathy (HCM) disease spectrum.
T he end stage (ES) phase of hypertrophic cardiomyopathy (HCM), characterized by systolic dysfunction, has previously been regarded as a not uncommon disease complication with a distinctively homogeneous clinical profile. [1] [2] [3] [4] [5] Previous characterization of ES has been based largely on single cases or small groups of patients. 4,6 -17 More recently, it has been our impression that the clinical spectrum of this HCM subset may be more diverse than previously appreciated and that its frequency may have been overestimated. Therefore, it is a particularly opportune time to offer a large measure of clarity to our understanding of the clinical profile, prognosis (including risk for heart failure or sudden death), and treatment strategies for the ES of HCM by revisiting this subset of the HCM disease spectrum in a large, multicenter population.
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Methods
Selection of Patients
The study population was composed of 1259 consecutively enrolled HCM patients, from 1983 to 2005, analyzed retrospectively at 3 centers: Minneapolis Heart Institute Foundation, Minneapolis, Minn (nϭ752); Ente Ospedaliero Ospedali Galliera, Genoa, Italy (nϭ354); and Tufts-New England Medical Center, Boston, Mass (nϭ153). Initial evaluation was the first clinical assessment of heart disease for which an echocardiogram was obtained or first visit to a participating institution. Most recent evaluation, 2.3Ϯ3.8 years (range 0.5 to 22) after initial assessment, was ascertained in patients while they were in the hospital or by telephone interview.
Definitions
Diagnosis of HCM was based on echocardiographic documentation of a hypertrophied nondilated left ventricle (LV) in the absence of another cardiac or systemic disease that could produce the magnitude of hypertrophy evident at some time during the natural course of the disease. 18 The ES phase of HCM was defined as an LV ejection fraction Ͻ50% at rest, reflecting global systolic dysfunction, at study entry or during follow-up, by 2D echocardiography.
Echocardiography
Echocardiograms were performed with commercially available instruments. Magnitude of LV hypertrophy and outflow obstruction were assessed as described previously. 18, 19 Mitral regurgitation was graded semiquantitatively (1 to 4ϩ scale), and scores were averaged. 20 Ejection fraction was calculated from 2D echocardiographic images with the modified Simpson's rule formula or area-length method. 21 
Cardiac Magnetic Resonance
Cardiac magnetic resonance (CMR) imaging was performed on Siemens Sonata-Avanto (Erlangen, Germany) or Philips Gyroscan ACS-NT (Best, the Netherlands) 1.5T whole-body scanners with dedicated cardiac coils. Breath-hold cine images were acquired in multiple short-axis and 3 long-axis slices with steady-state free precession sequences. Ventricular coverage was achieved with contiguous 10-mm-thick slices or 7-mm slices (3-mm gap). A delayed enhancement protocol was used 15 minutes after intravenous administration of 0.2 mmol/kg gadolinium-DTPA (Magnevist, Schering; Berlin, Germany) with breath-held segmented inversion-recovery sequence (inversion timeϭ240 to 300 ms) acquired in the same views.
Statistical Analysis
Data are expressed as meanϮSD. Two-tailed paired or unpaired Student t tests compared normally distributed data. 2 Tests compared noncontinuous variables expressed as proportions. Incidence of ES phase was calculated (for patients with normal ejection fraction at study entry) as the ratio of new cases (nϭ33) to the total number of HCM patients in the cohort over the follow-up period.
Occurrence of the ES phase in patients with or without a history of surgical septal myectomy was compared by calculating average annual occurrence rates over the follow-up period and expressing those as relative risk with z test with Yates correction. Confidence intervals (95% CIs) were calculated with the Poisson distribution and standard methods. Probability values were significant when Յ0.05.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Results
Occurrence ES of HCM was identified in 44 (3.5%; 95% CI 2.54% to 4.69%) of 1259 study patients, and this proportion was similar (Pϭ0.18) among the 3 centers: Minneapolis (3%), Genoa (5%), and Boston (3%). Eleven (25%) of 44 patients had ES at initial evaluation; the other 33 patients (75%) evolved into ES during follow-up. Incidence was 33 cases per 2946 person-years of follow-up (1.12 cases per 100 personyears; 95% CI 0.77 to 1.54).
Clinical Profile of ES
Age and Gender
The 44 ES patients were 40Ϯ16 years old (range 3 to 63) at initial evaluation and 48Ϯ18 years at the most recent evaluation, death, heart transplantation, or appropriate implantable cardioverter-defibrillator (ICD) intervention for ventricular tachycardia/fibrillation ( Figure 1 ). ES was identified at a wide range of ages, ie, 14 to 74 years (mean 45Ϯ16 years): Twenty patients (45%) were Յ40 years old, 9 (21%) were Յ30 years old, and 11 (25%) were Ն60 years old. Twenty-seven patients (61%) were male.
Seven of 44 patients had undergone surgical myectomy 1,2 many years before ES onset (18Ϯ5 years of age; Table) . ES occurrence in patients with myectomy was 7 of 89 (8% over 45 person-years), and in patients without myectomy, it was 37 of 1170 (3% over 288 person-years), which produced a relative risk for ES after myectomy of 1.21 (95% CI 0.51 to 2.26; Pϭ0.84). Also, myectomy and nonmyectomy patients did not differ with respect to adverse disease consequences, including death, transplantation, or appropriate ICD shocks (5/7 [71%] versus 26/39 [67%]; Pϭ0.9). Atherosclerotic coronary artery disease (Ն50% narrowing of at least 1 major artery) was excluded by angiography or pathological examination in 17 patients. One patient (patient 20) had an incidental finding of 95% focal narrowing of the left anterior descending coronary artery at autopsy. 
Remodeling Patterns
Four patterns of LV remodeling were identified: (1) Twentythree patients (52%) showed the most complete remodeling, with LV cavity enlargement (Ն55 mm end-diastolic) and/or increase in size, associated with relatively mild hypertrophy (Ͻ20 mm), and/or regression in septal thickness ( Figure 4 );
(2) 5 patients (11%) demonstrated enlarged and/or progressively increasing LV cavity dimension with preserved hypertrophy (Ն20 mm); (3) 11 patients (25%) had normal LV cavity size but relatively mild increase in septal thickness (Ͻ20 mm) and/or decrease during follow-up; and (4) 5 patients (11%) showed persistence of nondilated and markedly hypertrophied LV (septal thickness 20 to 39 mm; Figure  5 ). On initial evaluation, resting LV outflow gradients of 25 to 70 mm Hg due to mitral valve systolic anterior motion were evident in 5 patients (11%; patients 7, 21, 33, 36, and 42); no patient had a gradient at most recent evaluation. Mitral regurgitation scores increased from 1.0Ϯ0.9 to 1.5Ϯ1.1 at most recent evaluation (Pϭ0.003), when 20 (45%) of 44 patients showed moderate to severe regurgitant jets.
Clinical Course and Management
ES was identified 5Ϯ6 years after initial evaluation (at or near HCM diagnosis; Figure 1 ). Time from onset of HCM symptoms to ES recognition was considerable (14Ϯ10 years). In contrast, the interval from ES identification to death or transplantation was relatively brief (2.7Ϯ2 years; Figure 1 ). At study entry, 15 (34%) of 44 ES patients were asymptomatic in New York Heart Association functional class I, 20 (45%) had mild symptoms (class II), and 9 (21%) were severely limited due to exertional dyspnea (classes III/IV); of the 35 class I and II patients, 8 already showed systolic dysfunction.
In the presence of preserved LV systolic function, patients initially received standard medications for HCM, most commonly ␤-blockers and verapamil. After systolic dysfunction developed, patients were treated with afterload-reducing agents (64%; ACE inhibitors or angiotensin II receptor blockers), diuretics (68%), and ␤-blockers (50%), as well as digitalis (11%), spironolactone (11%), and warfarin when indicated.
Fifteen (34%) of the 44 patients have survived free of events with maximal medical treatment over 3Ϯ3 years, including 9 who remain in classes I/II (Table) . The other 29 patients (66%) have died either of progressive, unrelenting heart failure (nϭ8) or of sudden cardiac death (nϭ5) or have had ICD interventions (nϭ5; 2 subsequently died) or heart transplantation (nϭ13; 2 later died; Table; Figure 6 ). Annual adverse event rate of ES patients was 11% (95% CI 7.27% to 15.6%).
Five patients (28%) among 18 with ICDs experienced appropriate device interventions, including 4 who survived to present or to transplantation; all patients with ICD shocks had LV dilatation (Table; Figure 6 ). Appropriate intervention rate was 10% per year (95% CI 3.3% to 24.3%). Four patients had cardiac resynchronization therapy for 1 to 2 years before transplantation, with modest symptom improvement in 1 and none in the other 3.
Comparison of ES and Other HCM Patients
Compared with non-ES HCM patients, the 33 patients who developed ES after study entry were diagnosed at an earlier age (32Ϯ18 versus 42Ϯ20 years; Pϭ0.002), and at initial evaluation had more severe symptoms (New York Heart Association class 1.8Ϯ0.8 versus 1.4Ϯ0.6; Pϭ0.009), larger LV cavity (48Ϯ8 versus 44Ϯ6 mm; Pϭ0.03), thicker septum (25Ϯ6 versus 21Ϯ6 mm; Pϭ0.005), and less frequent outflow gradients Ն30 mm Hg at rest (13% versus 36%; Pϭ0.04). In addition, ES patients more often experienced atrial fibrillation (48% versus 14%; Pϭ0.002) and showed more symptom progression (to New York Heart Association class 3.0Ϯ0.9 versus 1.7Ϯ0.8; PϽ0.001).
CMR Imaging
Postgadolinium contrast CMR imaging was obtained in 6 ES patients (1, 2, 4, 13, 18, and 27; Table and Figure 7) . Each showed large isolated or confluent areas of delayed hyperenhancement indicative of fibrosis, frequently transmural, and distributed diffusely throughout ventricular septum and LV free wall. These areas of fibrosis predominantly involved midepicardial and subepicardial portions of the LV wall.
Pathological Findings
Native explanted hearts were available for examination in 6 patients. Two distinctive morphological patterns were evident. Two hearts showed dilated ventricular chambers associated with only mild ventricular septal thickening (ie, 15 and 13 mm; heart weights 320 and 350 g, respectively). Each showed diffuse or transmural scarring of septum and LV free wall, resulting in wall thinning.
The 4 other hearts (patients 4, 7, 8, and 20) had nondilated ventricular chambers associated with marked septal LV thickening (20 to 39 mm; weights 470 to 525 g; Figure 5 ). Two of these showed diffuse transmural scarring of septum and LV free wall (patients 4 and 8; Figure 5B , 5C, 5D, and 5F), whereas the other 2 had diffusely distributed, patchy areas of nontransmural fibrosis (patients 7 and 20). In each of 6 hearts examined, histopathology showed cardiac muscle cell disorganization ( Figure 5E ) and abnormal intramural coronary arteries typical of HCM 1, 22, 23 (Figure 5C and 5E ).
Discussion
The clinical expression of HCM has proved to be particularly heterogeneous, and awareness of the diverse disease spectrum and clinical course has expanded substantially over the last decade. [1] [2] [3] 18, 24, 25 A patient subset characterized by clinical progression, and largely known as the ES phase, has been described. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 26, 27 Much of the prior literature about ES is, however, confined to isolated or small groups of patients. 4,6 -17 Therefore, we have revisited the ES in a multicenter cohort of Ͼ1200 HCM patients, which included the largest group of ES patients reported to date. The present study represents an opportunity to investigate occurrence, diagnosis, pathophysiology, and prognosis of this unique HCM subset, information that ultimately impacts management strategies.
The data in the present study expand the clinical profile of the ES and differ considerably from previous accounts in several important respects. First, ES frequency was 3.5%, which suggests that reliance on earlier reports from tertiary HCM referral centers (prevalence up to 15%) 3,5 may have overestimated the occurrence of ES, probably largely because of patient selection biases. 3, 5 The relative infrequency with which ES occurs only underscores the importance of a high index of clinical suspicion. For example, the transition from a hypertrophied and nondilated state (with intact contractility) to one of systolic dysfunction appears to evolve gradually over substantial time periods often associated with development of atrial fibrillation (eg, average 14 years), which, if recognized, allows important alterations in management strategies to be readily instituted. These include transition of standard HCM medical therapy to drugs for systolic pump failure, as well as proper timing for heart transplantation evaluation, which is the only definitive treatment option for ES (when systolic dysfunction is evident with ejection fraction Ͻ50%).
The clinical course of ES proved to be variable, often unpredictable, but generally unfavorable. Overall, about two thirds of the study population have died of their disease, undergone heart transplantation, or had appropriate life- saving ICD shocks. The overall annual mortality rate of 11% per year is in sharp contrast to 1% per year for the overall HCM population. 1,2 Furthermore, after recognition of ES, patients experienced a generally precipitous course, in which on average Ͻ3 years elapsed from recognition of ES to heart transplantation or death. Therefore, once ES is in place, it usually adopts an aggressive course, and definitive management strategies may be required. However, profound clinical deterioration was not universal, given that almost one third of patients treated medically in the present study have experienced substantial periods of time with compensated heart failure (average 3 years).
Another issue that underscores the importance of timely ES recognition relates to our strategy of providing patients with prophylactic ICDs when systolic dysfunction is evident, to protect against lethal ventricular tachyarrhythmias while they await donor hearts. 24, 28, 29 This approach proved to be lifesaving in 5 patients who received appropriate defibrillation shocks. The appropriate intervention rate of 10% per year was similar to that reported in HCM patients implanted for secondary prevention. 24 These observational data suggest that ES can be regarded as another risk marker in HCM, and the prophylactic placement of ICDs in all ES patients is a reasonable clinical strategy. 24 We observed ES patterns of LV remodeling to be nonuniform and variable. Global LV systolic dysfunction was, by definition, the most consistent ES feature and often preceded other evidence of remodeling, as well as severe symptoms. For example, only about 50% of patients had evidence of complete remodeling with the triad of LV wall thickness regression, cavity dilatation, and reduced ejection fraction. Of particular note, more than one third of the ES patients showed a nondilated or persistently hypertrophied LV or both, and 5 of these patients underwent heart transplantation. The latter patients represent a novel and heretofore unappreciated subset within the ES spectrum and suggest that the descriptive term "dilated HCM" 4 -7,9,14 -16,26 is a misnomer for describing the ES.
However, although many ES study patients did not in fact exceed the outer limits for LV cavity size by echocardiography (established for a normal population) or progress to absolute LV dilatation over the period of observation, our serial data showed evidence for considerable enlargement of the LV chamber over time. Such enlargement was often considerable, given the small chamber size characteristic of HCM patients before remodeling, even though the end-diastolic dimension that was ultimately achieved did not necessarily exceed the normal cutoff value of 55 mm. Therefore, the sine qua non of ES is a functional abnormality (ie, systolic dysfunction; ejection fraction Ͻ50%), whereas other morphological changes common in ES, such as LV cavity dilatation and wall thinning, are evident less consistently. Clinical and demographic markers that reliably anticipate evolution to the ES could not be defined with precision, largely owing to the retrospective nature of the study design and the broad clinical profile of ES patients. Nevertheless, certain clinical profiles were associated with a greater likelihood of developing ES. Of particular note, we found 20% of probands in the present study had at least 1 relative with the ES, which suggests that affected relatives merit close follow-up for early detection of ES. In addition, compared with the general HCM population, patients who developed ES after study entry were more symptomatic, had larger LV cavity and thicker ventricular septum, and more frequently developed atrial fibrillation. Furthermore, in ES patients, HCM diagnosis was earlier by 10 years, which suggests that disease recognition in young patients may predispose to ES later in life. We found no evidence that posterior LV free wall hypertrophy was associated with evolution to ES, as previously suggested. 26 Although ES was identified in 7 study patients many years after septal myectomy, we found no evidence that surgery predisposes to ES.
On the other hand, our observations suggest a potential role for CMR in earlier detection of the propensity to develop ES (possibly even in advance of systolic dysfunction), by postgadolinium delayed hyperenhancement demonstrative of widespread LV nonviability. 30 These CMR patterns, presumed to represent fibrosis and replacement scarring, are consistent with our pathological observations and those of others 3,10,31 and are probably largely responsible for the striking disease process. 1, 2, 22, 25, 32 Mechanisms responsible for transformation of typical HCM to ES are unresolved. Intuitively, the expanded collagen matrix in HCM 33 would appear to offer a structural framework for substantial ventricular stiffness and consequently, a measure of protection from the ES. This raises the alternative possibility of a unique molecular or genetic susceptibility to ES. 34, 35 Clustering of Ն2 relatives with ES was evident in a significant minority of our families, and 3 were genotyped. In each case, the identified mutation was in ␤-myosin heavy chain or myosin-binding protein C genes, suggesting that ES does not result from a particular molecular defect. Because these are the most common HCM-causing mutant genes, 2 also known to cause the primary dilated form of cardiomyopathy, 35 it is perhaps not unexpected that such mutations would prove to be responsible for the ES phase of HCM, as well as for the frequent occurrence of both ES and sudden unexpected death in HCM families. 12 In conclusion, HCM with ES is more heterogeneous with respect to clinical expression, symptomatic course, and patterns of LV remodeling than previously regarded. Greater clarity about the occurrence, expanded clinical profile, and features of ES will promote earlier recognition of this disease evolution. This is paramount to ensure implementation of more effective management strategies directed toward appropriate pharmacological treatment of pump failure and atrial fibrillation, defibrillator implantation, and timely evaluation for heart transplantation.
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